Insulin Regulation of Lipolysis and Lipolysis Proteins
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 3/9/2019 |
| Start Date: | November 12, 2018 |
| End Date: | September 1, 2021 |
These studies will define the abnormalities in the adipocyte proteins that are involved in
the failure of insulin to suppress lipolysis normally in humans with upper body obesity and
will help discover the mechanism by which pioglitazone, a medication used to treat type 2
diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid
metabolism.
the failure of insulin to suppress lipolysis normally in humans with upper body obesity and
will help discover the mechanism by which pioglitazone, a medication used to treat type 2
diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid
metabolism.
1. The investigators will determine whether impaired insulin-induced suppression of
lipolysis (as measured by IC50) is related to the above mentioned lipolysis proteins in
groups of volunteers known to vary widely with regards to abdominal adipocyte size and
regulation of adipose tissue lipolysis.
2. The investigators will determine whether the improved insulin regulation of lipolysis
resulting from treatment with the PPARγ agonist pioglitazone, with or without weight
loss, can be linked to specific changes in sets of PPARγ-responsive adipocyte lipolysis
proteins in UBO adults.
lipolysis (as measured by IC50) is related to the above mentioned lipolysis proteins in
groups of volunteers known to vary widely with regards to abdominal adipocyte size and
regulation of adipose tissue lipolysis.
2. The investigators will determine whether the improved insulin regulation of lipolysis
resulting from treatment with the PPARγ agonist pioglitazone, with or without weight
loss, can be linked to specific changes in sets of PPARγ-responsive adipocyte lipolysis
proteins in UBO adults.
Inclusion Criteria
- Men and Women between the ages of 18 and 55.
- Women will be premenopausal
- Non obese adults BMI between 18-25
- Obese BMI 30-38
Exclusion Criteria
• Pioglitazone package insert of contraindications for use:
- Initiation in patients with established New York Heart Associations (NYHA) class III
or IV Heart failure.
- Use in patients with known hypersensitivity to pioglitazone or any other component of
ACTOSE.
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Phone: 507-255-6062
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
